Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine

Other criteria

• Patient group:
• Inclusion:; Diagnosis of DSM-5 schizophrenia, bipolar-I mania and mixed episodes with psychotic features, schizophreniform, schizoaffective, delusional, and unspecified schizophrenia spectrum and other psychotic disorders, established with SCID-P for DSM-5; age between 18 and 40 years old; antipsychotic exposure no greater than 50 mg of olanzapine equivalents (Gardner et al. AJP, 2010) in the 7 days previous to baseline assessments
• Exclusion:; neurological disorder, intellectual disability, history of severe head trauma (unconciousness >10 min); diagnosis of active substance use disorder (except for nicotine and cannabinoids [cannabinoids use is a risk factor for psychosis]); Healthy Volunteers (HV) group:
• Inclusion:; age between 18 and 40 years old
• Exclusion:; current or past psychiatric disorder (assessed with the SCID-NP; subjects with past history of anxiety or depressive disorders receiving no active treatment in the previous 12 months may be included); past or current diagnosis of neurological disorder, history of severe head trauma or diagnosis of active substance use disorder (except for nicotine or cannabinoids); and c) history of a psychotic disorder in first-degree relatives